Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal

Dec 12 (Reuters) - Amgen Inc (AMGN.O) on Monday agreed to buy Horizon Therapeutics Plc (HZNP.O) in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in the sector this year. The company will pay $116.50 in cash, a premium of nearly 20% to the stock's last…#refinitiv #chemocentryxinc #medicare #williamblair #bankofamerica #horizontherapeuticsplc #trimbleinc #coupasoftwareinc #coupasoftware #enbrel
Source: Reuters: Health - Category: Consumer Health News Source Type: news